The cell therapy sector is experiencing a paradigm shift in manufacturing: from bioreactor (ex vivo) to body (in vivo).
- Combination: The Drug Delivery Word Of The Year For 2026
- In Vivo LNP-Engineered Cytokine-Armored CAR Cells For Solid Tumors
- Electronic Drug Delivery Devices Market: Advancing Smart, Connected Healthcare
- Regulating For Patient Safety And Success With Combination Products
- FDA Issues Final Guidance For pH Adjuster Waiver Requests For Generic Drugs
- Strained Manufacturing, Complexity Stymie In Vivo Progress
- To Fight Cancer, Gene Editing Needs To Solve Its Delivery Problem
- Is Oncology Precision Medicine Coming of Age?
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Principles Of Raman Spectroscopy And Application To Pharma Development
Learn how Raman spectroscopy is used to analyze a chemical compound’s structure and examine an example of how this technique is used to analyze amorphous material created through hot-melt extrusion.
-
Delivering Macromolecules: Challenges Associated With The Delivery Of Biologic Drugs
Developers need to look beyond the formulation of a stable drug all the way to patient compliance. Numerous pitfalls exist along the journey to bring a biologic combination product to market. This integrated solutions program can help you simplify the journey.
-
Quality By Design Principles For Analytical Methods
A QbD approach was used to solve a high-performance liquid chromatography analytical method problem where impurity peaks had shifting retention times, making identification and quantitation problematic.
-
Nose To Brain (N2B) Drug Delivery – Benefits And Challenges
Delve into the growing interest in drug delivery methods that target the brain and central nervous system via absorption into the bloodstream, specifically focusing on crossing the blood-brain barrier (BBB).
-
Formulation Research Strategy For Discovery- Stage New Drug Candidates
Early stage formulation studies, which should support the emerging target product profile, will often yield important experimental results to aid subsequent development of clinically relevant dosage forms.
-
Prioritize Safety And Mitigate Risk In HPAPI Manufacturing
As highly potent active pharmaceutical ingredients become increasingly common across the industry, it is critical to work with partners who use a risk-based approach to ensure safety and quality.
-
Managing Poor Solubility With Cutting-Edge Formulation Approaches
An increasing number of poorly soluble APIs are the cornerstone of cutting-edge therapies, necessitating equally complex formulation technologies to maintain or improve solubility and, ultimately, bioavailability.
-
Ophthalmic Formulation Development: Inside Ophthalmic Preparation
Understand why the demand for CDMOs with experience in the formulation of ophthalmic products is on the rise.
-
Oral Controlled Delivery Of Poorly Water-Soluble Drugs
Various drug delivery nanotechnologies, such as nano-suspensions, lipid microemulsions, nano-emulsions, and amorphous solid dispersions, have been critical in overcoming bioavailability challenges.
-
Wet Milling Vs. Dry Milling In The Pharmaceutical Industry
Read about the considerations necessary for choosing between wet milling and dry milling for a specific active pharmaceutical ingredient.

